LYN

Across TCGA pan-cancer cohorts, LYN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LYN data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LYN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYN expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where LYN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	11	view →
HNSC	DFS	Median	All	0.914	0.987	.005	7	view →
CCRCC	OS	Median	III,IV	0.804	0.962	.034	6	view →
LSCC	DFS	Median	III,IV	0.944	0.642	.035	3	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
UCEC	OS	Quartile	All	1.000	0.900	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYN–LUAD (DFS)

Open the LUAD breakdown →